Skip to main content

Table 3 Cox regression model of multivariable analysis for OS and PFS

From: Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

 

OS

PFS

HR

95% CI

P value

HR

95% CI

P value

Gender

 Female

1

  

1

  

 Male

1.175

0.658–2.100

0.586

0.907

0.564–1.461

0.689

Age

 ≤ 50

1

  

1

  

 > 50

1.570

0.906–2.718

0.108

1.110

0.715–1.725

0.641

T stage

 T1

1

  

1

  

 T2

1.496

0.450–4.979

0.511

1.096

0.424–2.835

0.850

 T3

1.564

0.504–4.853

0.439

1.294

0.541–3.095

0.562

 T4

3.239

0.870–12.056

0.080

4.012

1.462–11.007

0.007

N stage

 N0

1

  

1

  

 N1

4.041

0.533–30.616

0.176

2.162

0.650–7.190

0.208

 N2

5.758

0.762–43.511

0.090

3.081

0.931–10.199

0.065

 N3

10.354

1.219–87.914

0.032

7.165

1.924–26.678

0.003

Nimotuzumab

 Without

1

  

1

  

 With

0.124

0.017–0.902

0.039

0.511

0.223–1.173

0.113

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us